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TOC Figure: Drug response screening, gene expression, and kinome signaling were combined across 
biomaterial platforms to combat adaptive resistance to sorafenib.   
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Insight Box 
We combined biomaterial platforms, drug screening, and systems biology to identify mechanisms of 
extracellular matrix-mediated adaptive resistance to RTK-targeted cancer therapies. Drug response was 
significantly varied across biomaterials with altered stiffness, dimensionality, and cell-cell contacts, and 
kinome reprogramming was responsible for these differences in drug sensitivity. Screening across many 
platforms and applying a systems biology analysis were necessary to identify MEK phosphorylation as 
the key factor associated with variation in drug response. This method uncovered the combination 
therapy of sorafenib with a MEK inhibitor, which decreased viability on and within biomaterials in vitro, but 
was not captured by screening on tissue culture plastic alone. This combination therapy also reduced 
tumor burden in vivo, and revealed a promising approach for combating adaptive drug resistance.   
 
Abstract  
  Traditional drug screening methods lack features of the tumor microenvironment that contribute 
to resistance. Most studies examine cell response in a single biomaterial platform in depth, leaving a gap 
in understanding how extracellular signals such as stiffness, dimensionality, and cell-cell contacts act 
independently or are integrated within a cell to affect either drug sensitivity or resistance. This is critically 
important, as adaptive resistance is mediated, at least in part, by the extracellular matrix (ECM) of the 
tumor microenvironment. We developed an approach to screen drug responses in cells cultured on 2D 
and in 3D biomaterial environments to explore how key features of ECM mediate drug response. This 
approach uncovered that cells on 2D hydrogels and spheroids encapsulated in 3D hydrogels were less 
responsive to receptor tyrosine kinase (RTK)-targeting drugs sorafenib and lapatinib, but not cytotoxic 
drugs, compared to single cells in hydrogels and cells on plastic. We found that transcriptomic differences 
between these in vitro models and tumor xenografts did not reveal mechanisms of ECM-mediated 
resistance to sorafenib. However, a systems biology analysis of phospho-kinome data uncovered that 
variation in MEK phosphorylation was associated with RTK-targeted drug resistance. Using sorafenib as 
a model drug, we found that co-administration with a MEK inhibitor decreased ECM-mediated resistance 
in vitro and reduced in vivo tumor burden compared to sorafenib alone. In sum, we provide a novel 
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strategy for identifying and overcoming ECM-mediated resistance mechanisms by performing drug 
screening, phospho-kinome analysis, and systems biology across multiple biomaterial environments. 
 
Introduction 
Adaptive resistance poses a significant challenge for targeted drugs as tumor cells can alter their 
signaling pathways to bypass the effect of therapeutics. This adaptive signaling occurs quickly and 
independently of acquired mutations, making the timing of therapeutics critical to sensitize tumor cells to 
drugs via rewiring from an oncogene-addicted state 1. For instance, triple-negative breast cancer cells 
treated with a MEK inhibitor undergo a rapid kinome reprogramming of many receptor tyrosine kinases 
(RTKs), cytokines, and downstream signaling pathways 2. Inhibition of this adaptive response by lapatinib 
prevents downstream Src, FAK, and Akt signaling 3. Mechanistically, kinase inhibitor treatment can 
decrease shedding of RTKs, thus enhancing bypass signaling 4. Drug treatment can also cause changes 
in the cell cycle, promoting resistance in the quiescent cells adapting to the treatment 5. These examples 
demonstrate that quick and widespread changes in signaling can occur in response to anti-cancer drugs.  
The tumor microenvironment is a complex, heterocellular system with known roles in modulating 
tumor progression and drug response 6. The extracellular matrix (ECM) is one feature of the 
microenvironment that can alter cell signaling and facilitate adaptive resistance. For example, ECM 
stiffness can activate RTKs and engage integrin binding to promote cell growth and survival through the 
Raf/MEK/ERK and PI3K/Akt/mTOR pathways 7, 8. Our group and others have employed engineered 
biomaterials to elucidate drug resistance in response to biophysical and biochemical stimuli from the 
ECM. Two-dimensional (2D) hydrogels allow for the presentation of controlled integrin binding, a 
physiological stiffness, and are amenable to drug screening. Three-dimensional (3D) hydrogels also 
present physiological dimensionality and biochemistry through matrix degradability, matrix adhesion, and 
homotypic or heterotypic cell-cell interactions. No single system can capture all features of the tumor 
microenvironment, and complex systems do not allow for isolation of the effect of individual cues. Here, 
we propose a biomaterial-based method to systematically vary stiffness, dimensionality, and cell-cell 
contacts  to analyze matrix-mediated adaptive resistance by measuring genetic and phospho-signaling 
changes. 
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All of these extracellular cues can alter the signaling networks targeted by cancer therapeutics. 
For example, β1 integrin-mediated tolerance to a BRAF inhibitor in vivo can be recapitulated by stiff 
synthetic matrices in vitro 9. We recently developed a high-throughput drug screening platform based on a 
poly(ethylene glycol)-phosphorylcholine (PEG-PC) hydrogel and identified that increased substrate 
stiffness imparts resistance to sorafenib 10, 11. Similarly, others have demonstrated decreased drug 
sensitivity in 3D hydrogels compared to 2D hydrogels and tissue culture polystyrene (TCPS) 12. These 
studies demonstrate the vast opportunities synthetic biomaterials provide for exploring drug resistance 
and rewiring mediated by features of the ECM but have yet to capitalize on the potential for a systematic 
analysis of stiffness, geometry, and cell-cell contacts afforded by such systems to understand 
mechanisms of ECM-mediated resistance.  
 It is imperative to consider multiple components of the ECM while studying drug response, as 
variations in matrix complexity can produce considerably different predictions for in vivo drug response to 
anti-cancer drugs. Since no single system can capture all features of the tumor ECM, we investigated 
drug resistance and adaptive reprogramming of breast cancer cells across multiple biomaterial 
microenvironments to analyze the genetic and phospho-signaling contributions to adaptive resistance. 
Multiple linear regression modeling revealed that MEK signaling explained the difference in RTK-targeted 
drug response across the ECMs, and co-administering a MEK inhibitor with sorafenib improved efficacy of 
the single agent in vitro and in vivo. This is the first report to combine systems biology analysis with 
screening across biomaterial platforms to identify MEK as a mediator of ECM-driven resistance to RTK 
inhibitors.  
 
Materials and Methods 
Cell culture 
All supplies were purchased from Thermo Fisher Scientific (Waltham, MA) unless otherwise noted. 
Human breast cancer cell lines MDA-MB-231 and SkBr3 cells were generous gifts from Dr. Sallie Smith 
Schneider at the Pioneer Valley Life Sciences Institute and Dr. Shannon Hughes at the Massachusetts 
Institute of Technology, respectively, and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
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supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5% 
CO2. 
 
Polymerization of 2D and 3D PEG hydrogels 
2D PEG-phosphorylcholine (PEG-PC) hydrogels were prepared and protein was coupled as described 
previously 10. Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific, Sunnyvale, CA) 
were plasma treated (Harrick Plasma, Ithaca, NY) and subsequently methacrylate-silanized with 2 vol % 
3-(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich, St. Louis, MO) in 95% ethanol (pH 5.0) for 5 min, 
washed 3 times with 100% ethanol, and dried at 40°C for 30 minutes. PEGDMA (Mn 750, Sigma-Aldrich), 
is added at 1.1 wt % (10 kPa, 0.015 M) or 3.2 wt % (33 kPa, 0.043 M) to a solution of 17 wt % 2-
methacryloyloxyethyl phosphorylcholine (PC) (Sigma-Aldrich) in phosphate-buffered saline (PBS). 
Solutions were sterilized with a 0.2 μm syringe filter (Thermo) and degassed by nitrogen sparging for 30 
seconds. Free-radical polymerization was induced by addition of 0.05 wt % ammonium persulfate (APS, 
Bio-Rad Laboratories, Hercules, CA) and 0.125 vol % tetramethylethylenediamine (TEMED, Sigma-
Aldrich). Hydrogels of 40 μL per well in the 96-well plates were polymerized under nitrogen for 30 
minutes. Post-polymerization, hydrogels were allowed to swell for 24 hours in PBS, then treated with 100 
μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5 HEPES buffer) under UV light for 
20 minutes, rinsed twice with HEPES buffer, and followed immediately by incubation with type I collagen 
at 3.3 μg/cm2 (Thermo) overnight.  
3D PEG-maleimide (PEG-MAL) hydrogels were prepared at 10 wt % (3 kPa) and 20 wt % (5 kPa) 
solution with a 20K 4-arm PEG-MAL (Jenkem Technology, Plano, TX) and 2mM of the cell binding 
peptide CRGD (Genscript, Piscataway, NJ), and was crosslinked at a 1:1 ratio with 1K linear PEG-dithiol 
(Sigma-Aldrich) in 2mM triethanolamine (pH ~ 7.4) 13. Hydrogels were polymerized in 10 μL volumes for 5 
minutes before swelling in cell culture medium.  
Bulk diffusion of Rhodamine 6G (R6G) (Stokes’ radius 0.76 nm, Sigma-Aldrich) in 3D PEG-MAL 
hydrogels was measured by encapsulating 0.1 g/L R6G in the hydrogel and sampling the supernatant at 
5-minute intervals. The samples were analyzed on a fluorescent plate reader at excitation: 526 
nm/emission: 555nm. The diffusion coefficient of R6G was calculated using the Stokes’-Einstein equation.  
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Formation of uniform tumor spheroids 
Lyophilized poly(N-isopropylacryamide)-poly(ethylene glycol) (polyNIPAAM, Cosmo Bio USA, Carlsbad, 
CA) was reconstituted in cell culture medium according to the manufacturer’s instructions and kept at 4ºC 
until use. Cells were suspended in polyNIPAAM solution placed on ice at a density of 100,000 cells/mL 
for SkBr3 cells and 167,000 cells/mL for MDA-MB-231 cells, and each gel was made at a volume of 150 
μL. Gelation occurred after 5 minutes at 37ºC, and gels were swollen in cell culture medium. Single cells 
were grown into spheroids for 14 days in the gels with regular medium changes. Spheroids were either 
dissociated back onto TCPS (for RNA-Seq and drug dosing) or encapsulated in 3D PEG-MAL gels (for 
RNA-Seq, drug dosing, and signaling) for 24 hours.  
 
Hydrogel mechanical characterization 
Mechanical compression testing for 2D and 3D hydrogels was performed with a TA Instruments AR-2000 
rheometer (New Castle, DE) at a 2 μm/s strain rate and analysis as previously described 11. Indentation 
testing for polyNIPAAM hydrogels was performed using a custom-built instrument previously described 14. 
For this application, a flat punch probe with a diameter of 1.5 mm was applied to samples at a fixed 
displacement rate of 5 μm/s, for maximum displacement of 100 μm.  PolyNIPAAM samples were placed 
on a heated surface to maintain a sample temperature between 37-40°C throughout testing.  
 
Quantification of drug response  
At 24 hours post-seeding, cells on biomaterials were treated with lapatinib (0-64 μM, LC Laboratories, 
Woburn, MA), sorafenib (0-64 μM, LC Laboratories), temsirolimus (0-80 μM, Selleckchem, Houston, TX), 
doxorubicin (0-32 μM, LC Laboratories), or dimethyl sulfoxide (DMSO, Sigma-Aldrich) as a vehicle 
control. Where noted, inhibitors were included in the medium: PD0325901 (3 μM, Sigma-Aldrich), 
SP600125 (20 μM, LC Laboratories). After 48 hours of drug treatment, cell viability was quantified by 
CellTiter Glo Luminescent Cell Viability Assay (Promega, Madison, WI), and luminescence was read on a 
Biotek Synergy H1 plate reader after incubation for 10 minutes. Separately, at 24 hours, viability of 
untreated cells was determined via CellTiter Glo for a measurement of initial seeding density. IC50 and 
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GR50 15 values were calculated using the initial seeding density and drug treated measurements using 
GraphPad Prism v6.0h.  
 
Cell seeding on biomaterials  
Cells were seeded on and in biomaterial microenvironments in serum-free DMEM (1% P/S, 20 ng/mL of 
epidermal growth factor (EGF), R&D Systems, and 20 ng/mL of platelet-derived growth factor BB (PDGF-
BB), R&D Systems, Minneapolis, MN) or serum containing DMEM (1% P/S and 10% FBS) where noted. 
Cells were seeded at 30,000 cells/cm2 on PEG-PC gels and on tissue culture plastic (TCPS), or as single 
cells at 500 cells/μL in 3D PEG gels. Spheroids were recovered via addition of cold serum free medium 
(1% P/S) on ice for 5 minutes for gel dissolution, and then gravity sedimentation for 30 minutes on ice. 
The supernatant was removed and the spheroids collected from each polyNIPAAM gel were re-
suspended in PEG-MAL solution to make 9 3D hydrogels.  
 
RNAseq 
Total RNA was isolated using Gen Elute mammalian total RNA miniprep kit (Sigma-Aldrich). The Illumina 
TRUseq RNA kit was used to purify and fragment the mRNA, convert it to cDNA, and barcode and 
amplify the strands. Quality and length of the inserts was confirmed with an Agilent Genomics 2100 
bioanalyzer, followed by single-end reads on a NextSeq 500 to generate a complete transcriptome from 
each sample. Transcripts were aligned to the hg19 human reference genome using the Tuxedo Suite 
pathway 16. 
 
Gene Set Enrichment Analysis 
Aligned samples were converted to GCT and CLS file formats using useGalaxy.org 17. Samples were 
separated by material condition across both cell lines to determine biomaterial microenvironment-specific 
gene categories. GSEA software was used to analyze enriched KEGG pathways as previously described 
18, and pathways with significant enrichment of expressed genes were selected 19. 
 
Multiplex phospho-protein quantification 
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Cells were seeded onto 2D hydrogels at 56,600 cells/cm2, or into 3D gels at 200,000 single cells in 20 μl 
volume gel. Spheroids were grown for 14 days in polyNIPAAM, and then transferred to 3D PEG-MAL 
gels, where spheroids from three polyNIPAAM gels were transferred to four 20 μl 3D PEG-MAL gels. 
Samples were seeded in serum free DMEM. After 24 hours, cells were dosed with either 8 μm sorafenib, 
8 μm lapatinib, 25 μm temsirolimus, or DMSO control in serum free medium (or serum containing medium 
where noted) for 4 hours, then washed once with ice cold PBS and lysed in RIPA buffer supplemented 
with protease (EDTA-free protease inhibitor cocktail tablets, 1 tablet in 10 ml, Roche, Indianapolis, IN) 
and phosphatase (1x phosphatase inhibitors cocktail-II, Boston Bioproducts, Boston, MA) inhibitors, 1 mM 
phenylmethylsulfonyl fluoride (Thermo Fisher Scientific), 5 μg/ml pepstatin A (Thermo Fisher Scientific), 
10 μg/ml of leupeptin (Thermo Fisher Scientific), 1 mM sodium pyrophosphate (Thermo Fisher Scientific), 
25 mM β-glycerophosphate (Santa Cruz, Dallas, TX). Protein concentration was determined with a BCA 
assay (Sigma-Aldrich). PEG-MAL gels were manually dissociated with a pipet tip for 30 seconds after 
addition of lysis buffer.  
Lysate concentrations were adjusted to 520 μg/ml and then analyzed with the MILLIPLEX MAP 
Multi-Pathway Magnetic Bead 9-Plex - Cell Signaling Multiplex Assay (Millipore, Billerica, MA; analytes: 
CREB (pS133), ERK (pT185/pY187), NFκB (pS536), JNK (pT183/pY185), p38 (pT180/pY182), p70 S6K 
(pT412), STAT3 (pS727), STAT5A/B (pY694/699), Akt (pS473) supplemented with additional EGFR (pan 
Tyr) and MEK1 (pS222) beads according to the manufacturer’s instructions, with the exception that beads 
and detection antibodies were diluted four-fold. Controls were performed to ensure that samples were 
within the linear dynamic range. Data is reported as the Mean Fluorescent Intensity (MFI) or fold change 
in MFI relative to the vehicle control.   
SkBr3 cells on TCPS, 33 kPa 2D gels, and spheroids in 3 kPa PEG-MAL were serum starved for 
24 h and then stimulated with 100 ng/mL of EGF (R&D Systems, Minneapolis, MN), and cell lysates were 
collected at 0, 5, 15, 60 minutes, and 24 hours time points. Lysate concentrations were adjusted to 160 
μg/mL, and samples were quantified the MILLIPLEX MAP Phospho Mitogenesis RTK Magnetic Bead 7-
Plex Kit (Millipore; analytes: c-Met/HGFR (panTyr), EGFR (panTyr), ErbB2/HER2 (panTyr), ErbB3/HER3 
(panTyr), ErbB4/HER4 (panTyr), IR (panTyr), and IGF1R (panTyr) according to the manufacturer’s 
instructions, with the exception that beads and detection antibodies were diluted four-fold. 
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Experimental Model And Subject Details 
Multiple linear regression modeling was performed using ‘stats::lm’ within R, regressing each 
compendium of signaling measurements against the corresponding viability measured in the same 
conditions. All relationships were assumed to be additive, and no interaction or intercept terms were 
included in the models. Each measurement was z-score normalized before regression. The two-sided p-
values presented were calculated based upon the significance of each parameter being non-zero. The 
overall performance of each model (as calculated by the F-statistic) corresponded well to the significance 
of individual terms. All code and raw measurements for model development are available on Github 
(https://github.com/meyer-lab/Barney-Peyton). 
 
Immunofluorescence and immunohistochemistry 
Cells were grown in serum for 24 h in the indicated material condition, fixed, and stained for Ki67. Cells 
were serum-starved and stimulated with EGF as described above, and stained according to standard 
protocols for total EGFR or HER2. The following antibodies were used for immunofluorescence: Ki67 
(ab16667, 1:200, Abcam), EGFR (D38B1, 1:100, Cell Signaling Technology), and HER2 (29D8, 1:200, 
Cell Signaling Technology). All tumor samples were fixed and paraffin embedded. Ki67 staining 
(ab16667, 1:100, Abcam) was done on 6 μm tissue slices. All Alexa Fluor secondary antibodies (Thermo 
Fisher Scientific) were used at 1:500. Samples were imaged on a Zeiss Cell Observer SD (Carl Zeiss AG, 
Oberkochen, Germany).  
 
Animal Xenografts 
All animal experiments were in accordance with institutional guidelines and approved by the Institutional 
Animal Care and Use Committee at the University of Massachusetts Amherst. UMass has an approved 
Animal Welfare Assurance (#A3551-01) on file with the NIH Office of Laboratory Animal Welfare. MDA-
MB-231 cells were suspended in Matrigel (Corning, Corning, NY), and 106 cells were subcutaneously 
injected into the mammary fat pad of 8-10 week old female NOD scid gamma mice from a breeding 
colony. Each mouse was injected with two tumors. All mice were housed in ventilated cages with sterile 
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bedding, food, and water. Injected cells were grown in vivo for 7 days then drugs were suspended in 
DMSO and administered with an intraperitoneal (IP) injection daily for 14 days using a 27-gauge needle.  
Mice received 100 μL of one of five different treatments: vehicle (100% DMSO), sorafenib at 10 mg/kg, 
PD0325901 at 10 mg/kg, or a combination of the drugs at 5 or 10 mg/kg each. A minimum of 4 mice were 
analyzed for each drug dosing condition, and each tumor was considered one replicate. 
 
Quantification And Statistical Analysis 
Prism v5.04 (GraphPad Software) was used to perform unpaired Student's t-test, a one-way analysis of 
variance (ANOVA) with a Tukey post-test. A two-way ANOVA determined how the IC50 changed with 
respect to material modulus, geometry, and medium condition, with a Bonferroni post-test (GraphPad 
Prism v5.04).  A two-way ANOVA, performed in R, was used to determine drug contribution to tumor 
burden. Data are reported as mean ± standard error, where p ≤ 0.05 is denoted with *, ≤ 0.01 with **, and 
≤ 0.001 with ***. 
 
Results 
Geometry impacts innate breast cancer cell response to RTK/MAPK-targeting drugs 
Distinct differences across in vitro screening methods, including stiffness, dimensionality, and 
cell-cell interactions prevent comparisons across existing studies. Therefore, we developed a system to 
independently evaluate the effects of both the geometry and stiffness of the microenvironment on breast 
cancer cell response to targeted and non-targeted drugs. We measured the GR50 (concentration of drug 
which dampens growth by 50%) 15 for four drugs (sorafenib, lapatinib, temsirolimus, and doxorubicin) 
across multiple biomaterials: TCPS, a 2D PEG-PC hydrogel, and a 3D PEG-MAL hydrogel with 
encapsulated single cells or tumor spheroids (Figure 1a). To create tumor spheroids, single cells were 
encapsulated sparsely in polyNIPAAM hydrogels and grown into uniform clonal spheroids over 14 days in 
culture (Figure 1b-d). This 14 day endpoint achieves a relatively homogeneous population of viable 
multicellular tumor spheroids with an average diameter less than 100 μm (Figure 1b-c) 20. This diameter 
was chosen to ensure drug 21 and oxygen diffusion into the spheroids. Spheroids were transferred to 
PEG-MAL hydrogels for dosing, where bulk diffusion measurements of rhodamine 6G suggest small 
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molecules diffuse through the 3D hydrogel at 2.5x10-6 cm2/s (data not shown), which means that the drug 
will reach the cells within 10 seconds. Further, immunofluorescent staining of Ki67 expression revealed 
that there were proliferating cells throughout the entire spheroid, suggesting there were no significant 
nutrient or oxygen diffusion limitations within the 3D PEG hydrogel (Figure S1).  
We previously found that breast cancer cells on stiffer substrates were more resistant to sorafenib 
10, so we included two different moduli for the 2D and 3D hydrogels (Figure S2). Although the effect of 
altered proliferation across the biomaterials (Figure 1e-f) would confound comparisons of traditional IC50 
calculations, it is accounted for in the GR50 calculation 15. Therefore, the differences we report in drug 
response are a direct result of ECM-driven resistance, independent of a growth advantage. In Figure 1e-f, 
drug response is reported as a fold change in GR50 from the indicated condition compared to TCPS, 
where red indicates resistance and blue indicates sensitivity compared to TCPS. Response to 
doxorubicin did not vary significantly across geometry, modulus, or medium (with or without serum, varied 
for the spheroid model only) in either cell line (Figure 1e-f, Figure S3). Response to temsirolimus was not 
dependent on platform in the MDA-MB-231 cells, while in the SkBr3 cells, geometry and medium, but not 
modulus, had a small, but significant, impact on GR50. However, sorafenib and lapatinib response varied 
considerably across the biomaterial platforms, particularly in the MDA-MB-231 cells (Figure 1e-f, Figure 
S3). It is notable that the SkBr3 response to sorafenib was only dependent on geometry, and not the 
addition of serum, suggesting a unique role for the ECM in mediating drug response, independent of 
exogenous mitogenic factors.  A two-way analysis of variance (ANOVA) showed that the changes in 
geometry and medium had a larger effect on total variance than the change in modulus as reported by 
the percent of variation across biomaterial platforms (Table S1). Within each geometry, we observed no 
significant difference in drug response at either stiffness, and we encourage the reader to view the bar 
graphs and statistical analysis provided in the electronic supplementary information (Table S1, Figure 
S3), indicating that cancer cell resistance to sorafenib and lapatinib was most sensitive to changes in 
geometry within this modest stiffness range.  
 
Gene expression is not responsible for ECM-driven differences in drug response  
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We performed RNA-seq on MDA-MB-231 and SkBr3 cells cultured on TCPS, on 2D hydrogels, 
as tumor spheroids, and as a tumor xenograft (Figure 2a). Hierarchical clustering of differentially 
expressed genes first separated samples by the cell line, then by material platform (Figure S4). The 
biomaterial platform dictated clustering within each cell line and dimensionality had greater influence on 
clustering than stiffness. Gene expression on the 2D hydrogels (10 and 33 kPa) was similar for both cell 
lines, and these samples are closely related to cells on TCPS. Toward understanding whether this was an 
immediate effect of signals from the ECM or from selective growth of a subset of cells in different 
environments, we also analyzed cells initially grown into spheroids, but then dissociated and cultured 
back on TCPS for 24 hours. The gene expression profile from these dissociated spheroids was also 
closely related to the other 2D conditions, indicating this expression was likely derived from the assay 
platform, rather than the culture platform (Figure 2a).  
Gene set enrichment analysis (GSEA) identified several significantly enriched pathways in one or 
more of the biomaterials. For example, genes associated with the regulation of growth and receptor-
linked signal transduction are upregulated in MDA-MB-231 cells on plastic compared to MDA-MB-231 
cells in 3D spheroids (Figure 2b). While this is not an exhaustive list, cells on TCPS expressed more 
cytokine and associated receptor genes and cells in the xenograft upregulated expression of ECM 
components, particularly collagens and keratins.  In Figure 2c and d, the normalized enrichment scores 
are plotted as pairwise comparisons, enriched in the row condition over the column platform in red for 
MDA-MB-231 cells and in blue for SkBr3 cells.  As expected, both cell lines upregulated genes 
associated with growth regulation on TCPS compared to all the other conditions we examined (Figure 1e-
f, Figure 2b-c). Furthermore, the MDA-MB-231 xenograft tumors upregulated growth-related genes 
compared to cells grown in vitro as spheroids, suggesting that the mouse host environment provided 
additional growth cues (Figure 2c). However, both geometry and stiffness influenced surface receptor 
linked signal transduction. For example, cells on TCPS universally showed enrichment for these genes 
compared to the other biomaterials, and our spheroids showed enrichment over the 2D hydrogels in the 
SkBr3 cells (Figure 2d).  
We then used this expression data to determine if ECM-mediated drug response was a result of 
changes in the gene expression of drug targets for lapatinib and sorafenib across the biomaterials (Figure 
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1e-f). We found no correlation between expression of these target genes and the GR50 (Figure 2e,g). 
However, both of these drugs are known to alter signaling of many other pathways, and a literature 
search identified several known unintentional targets or resistance mechanisms for each drug 22-26 (Figure 
2f,h). Although many of these genes showed little to no change in expression across the biomaterials, we 
did note that AXL expression showed a slight positive trend, but not a significant correlation, with lapatinib 
response in the MDA-MB-231 cells (Figure 2f). AXL has previously been shown to predict drug resistance 
to ErbB targeted inhibitors in many cancer types 26, but does not appear to significantly contribute to the 
drug responses examined here.  
 
Multiple linear regression reveals that using a MEK inhibitor with sorafenib is an effective 
combination therapy 
Since there were large differences in GR50 across the screening microenvironments, and known 
drug targets were not responsible for ECM-mediated resistance, we hypothesized that plasticity in 
intracellular signaling networks was responsible for the differential responses. We measured a panel of 
phospho-proteins associated with RTK signaling at basal levels and in response to drug treatment across 
the biomaterial ECMs. Here, we chose to closely examine sorafenib and lapatinib across material 
platforms, and added temsirolimus to compare to a drug whose response was largely independent of 
ECM (Figure 1e-f).  
The basal levels of nearly every analyte were significantly lower in 3D than on 2D ECMs (Figure 
3a-b), which matches growth and signal transduction gene signatures from our expression data (Figure 
2c-d). As expected, drug treatment reduced the phosphorylation level of the intended targets (Figure 3c-
d). However, we only observed significant reduction in known targets and increases in adaptive pathways 
in 2D, suggesting that the 3D environment suppresses drug efficacy through dampened signaling and 
kinome rewiring. Dimensionality-dependent signaling differences were also present during direct 
activation of the receptor by its cognate ligand. When stimulated with epidermal growth factor (EGF) on 
TCPS, pEGFR was elevated within 5 minutes, and EGFR was internalized within an hour (Figure S5a-c). 
When spheroids were encapsulated in 3D hydrogels, pEGFR and pHER2 were still stimulated at 5 
minutes, but only modestly, and EGFR localization did not change with EGF stimulation (Figure S5a-f).  
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Our lab has previously demonstrated the role of JNK in stiffness-dependent sorafenib resistance 
10. Because we observed increased pJNK in response to the drug treatments in both cell lines, we 
hypothesized that JNK may mediate drug response across the biomaterials. Co-administration of JNK 
inhibitor SP600125 sensitized the MDA-MB-231 cells to sorafenib on 2D biomaterials and as spheroids 
with serum, as well as TCPS (Figure 3e). SP600125 only sensitized the SkBr3 cells in the spheroid and 
2D hydrogel conditions, but not the stiff TCPS environment, perhaps a result of the very high increase in 
pJNK in the sorafenib-treated SkBr3 cells in that environment (Figure 3g). We separately examined JNK 
phosphorylation after treatment with doxorubicin, a non-targeted drug that provoked low variability across 
platforms, and found that JNK signaling was still altered by drug treatment. This suggests that here JNK 
may be caused by drug-induced stress, but does not significantly contribute ECM-mediated resistance 
(Figure S6a-b). Further, the efficacy of the JNK inhibitor in the MDA-MB-231 spheroids in the 3D hydrogel 
was mirrored in the simple TCPS assay, and did not need screening across biomaterials for discovery. 
Thus, we sought to identify an efficacious combination therapy using this multi-environment screening 
approach that could not be identified through simple TCPS screening.  
Multiple linear regression (MLR) models revealed non-intuitive relationships between the 
sorafenib-, lapatinib-, and temsirolimus-treated signaling and drug response data for both cell lines across 
the biomaterials. This model was constructed from phosphorylation data of 10 analytes 4 hours after 
targeted drug treatment at 15 conditions, including 3 drugs, and 5 biomaterial platforms per drug. 
Although targeting the MEK/ERK pathway was not an obvious choice from the signaling data (Figure 3c-
d), these models revealed that variability in MEK phosphorylation was the key factor associated with 
viability in response to drug treatment in MDA-MB-231 cells (Figure 3f,h).  Here it is important to note that 
the MLR output includes the contribution of each signaling analyte to drug response, and that while MEK 
was identified as the key factor, other analytes have non-zero contributions to the model. To determine 
the necessity of modeling cell response across several biomaterial platforms and drugs, we performed 
subsequent analyses where we independently excluded either all 3D conditions (single cells, spheroids, 
spheroids with serum) or 2 of the drugs (lapatinib and temsirolimus). Neither of these modified models 
achieved significance (Figure S7a). Returning to our model that includes all 3 drugs in the MDA-MB-231 
cells, we determined that each 3D condition could be excluded independently, but that TCPS, 2D 
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biomaterials, and at least one 3D condition were necessary to predict MEK phosphorylation as a likely 
mechanism of ECM-mediated resistance (Figure S7b).  
We next co-administered both sorafenib and the MEK inhibitor PD0325901 to cells in the different 
biomaterials. In both cell lines, there was no improved efficacy when co-treating sorafenib and 
PD0325901 on TCPS (Figure 3e,g). However, both cell lines were sensitized to sorafenib when co-
administered with PD0325901 in the 2D hydrogel and spheroid conditions (Figure 3e,g). This suggests 
MEK may be a more physiological resistance mechanism to sorafenib, as SkBr3 cells did not show 
significant variability of MEK across platforms, but were still responsive to co-treatment in our 
biomaterials. Interestingly, the MDA-MB-231 cells are KRAS mutant, while the SkBr3 cells are not, 
meaning this treatment is independent of both this mutation and their clinical subtype. Altogether, the 
identification of MEK as an effective target for combination therapy was only realized through screening 
across many biomaterials and using a systems approach to analyze a phospho-signaling dataset. 
Likewise, the efficacy of the MEK inhibitor in combination with sorafenib was only achieved through 
screening in the more complex 2D or 3D biomaterial microenvironments, and would be missed using 
TCPS or via genetic analysis alone.  
 
MEK inhibition improves sorafenib efficacy in vivo  
Given the promising in vitro results with the MEK inhibitior, we tested PD0325901 as a 
combination therapy with sorafenib in an in vivo model. MDA-MB-231 tumors were inoculated in the 
mammary fat pad of NSG mice and allowed to grow for 7 days, at which point all mice had palpable 
tumors.  From days 7 to 21, we treated daily with one of four regimens: 1) vehicle control (DMSO), 2) 10 
mg/kg sorafenib, 3) 10 mg/kg PD0325901, or 4) co-treatment of 10 mg/kg each sorafenib and 
PD0325901 (Figure 4a). As combination therapies are often associated with increased adverse events 27, 
we also included a fifth treatment group which received a lower dose of the combination therapy at 5 
mg/kg each of sorafenib and PD0325901. All of these doses were found to be well tolerated by mice in 
separate experiments (data not shown), although future work will need to better optimize the doses of this 
combination therapy for optimal clinical efficacy.  PD0325901 was the most effective single agent inhibitor 
and, as predicted in the 2D hydrogel and spheroid screening models, co-treating mice with PD0325901 
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and sorafenib had the most significant reduction in tumor burden, cellularity, and proliferation (Figure 4b-
d). In the lower concentration combination therapy (5 mg/kg each), reduction in tumor weight was 
comparable to 10 mg/kg PD0325901 alone (Figure 4b). A two-way ANOVA showed that PD0325901 
(Fvalue=54.7, p<0.001) contributed more to the decrease in tumor burden than sorafenib (Fvalue=8.2, 
p<0.01). The combination therapy of sorafenib and PD0325901 additively decreased tumor burden 
(Fvalue=0.3, p=0.6).  
 
Discussion 
By screening drug response across many ECMs, we identified that breast cancer cell response to 
sorafenib (Ras/Raf/MEK/ERK targeted) and lapatinib (EGFR-HER2 targeted) was significantly dependent 
upon the biomaterial environment (Figure 1e-f). Gene expression of known drug targets was unchanged 
across the ECMs (Figure 2e-h), but a systems analysis of phospho-kinome signaling in response to drug 
treatment across our different biomaterials revealed MEK as a key contributor to the variation in observed 
ECM-mediated resistance (Figure 3f). Although the combination therapy did not improve drug response in 
cells on TCPS, a MEK inhibitor in combination with sorafenib eliminated the matrix-mediated response in 
biomaterials in vitro and reduced tumor burden in vivo (Figure 4e). 
While most current literature examines signaling changes within a single platform 28-31, we applied 
MLR across five ECM conditions and three targeted drug treatments to determine which phospho-
proteins varied significantly with ECM-mediated drug response. This approach captures multiple aspects 
of the ECM that may contribute to drug response in vivo, including ECM stiffness, dimensionality, and 
cell-cell contacts using both 2D and 3D biomaterials. Synthetic 2D biomaterials allow for the presentation 
of full length proteins, while spheroids encapsulated in 3D better recapitulate tumor geometry. 
Importantly, cells seeded onto 2D biomaterials or as single cells in 3D only resided in that platform for 24 
hours, so they likely relied exclusively on the provided collagen I (2D) or RGD (3D) for biochemical 
signals. However, breast cancer cells grown as spheroids upregulate ECM genes, such as fibronectin, 
suggesting additional ECM cues might contribute to resistance 20. Recent work has shown that the ECM-
mediated signaling can impart resistance to combined inhibition of PI3K and HER2 32, but our method 
identified that targeting two nodes in the same pathway, Raf with sorafenib and MEK with PD0325901, is 
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a promising combination therapy for breast cancer. This non-intuitive co-treatment, which would not be 
identified by screening on traditional TCPS, suggests a similar approach may be beneficial in identifying 
combination therapies for kinome-targeting drugs, where adaptive resistance is frequently mediated by 
the ECM 10, 12. 
Combination therapies with MEK inhibition are effective in many cancer types 33-36. In fact, MEK 
inhibition is currently under evaluation in clinical trials because many cancers activate MEK signaling as a 
form of acquired resistance 37. Such combination therapies are often designed to limit adaptive survival 
signaling, and generally target two distinct pathways. Interestingly, in our work, co-targeting MEK 
improved sorafenib efficacy in vitro and in a pre-clinical in vivo tumor regression model, even though both 
drugs target the same pathway (Figure 4b). Others have seen similar improved efficacy in HER2+ breast 
cancer when co-treating the HER2-targeted drugs lapatinib and trastuzumab, suggesting that 
combination therapies targeting the same pathway can have improved effects by overcoming acquired 
resistance 38. However, not all cells within a tumor contribute equally to drug response. Tumors are highly 
heterogeneous and subpopulations can evade both cytotoxic and targeted therapeutics via upregulation 
of drug transporters, mutations of drug targets, adaptive signaling, and other mechanisms 2, 39, 40. Here we 
identified the additive effect of co-dosing with sorafenib and a MEK inhibitor on bulk tumor properties, but 
further work is necessary to understand the contribution of individual populations to resistance. 
We measured a large panel of phospho-proteins to see if the biomaterial environment facilitated 
phospho-signaling changes in response to the drug treatments that were associated with drug sensitivity 
or resistance. In our soft 3D environments, basal and drug-stimulated signaling were significantly 
suppressed, in agreement with other data in spheroids and on soft substrates 41-43. JNK appears to be a 
broad adaptive response 44, 45; however, MLR identified MEK as the most significant driver of ECM-
mediated resistance to sorafenib. ERK is downstream of both the lapatinib and sorafenib targets, which 
may explain why MEK/ERK signaling was so critical to drug response in our data. In agreement with our 
findings, myeloid leukemia cells have a stiffness-dependent response to drugs, including sorafenib and a 
MEK inhibitor, which target the RAF/MAPK pathway 46, 47. We have previously shown that sorafenib 
resistance increased with increasing hydrogel stiffness 10, and many others have also demonstrated that 
stiffness is a significant driving force for drug resistance 9, 10, 28, 29, 48-51. Thus, we were surprised to find 
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that drug resistance was only minimally affected by stiffness within the modest range examined here 
(Figure 1e-f). However, in our data, dimensionality contributed more to drug resistance than stiffness.  
Previous work has similarly shown that cancer cell spheroids are more resistant to paclitaxel than a 
monolayer 30, and the matrix-attached cells in spheroids are resistant to PI3K/mTOR inhibition 31.  
Because cells are less able to form cell-matrix adhesions on soft versus stiff 2D substrates, and 
in 3D versus 2D environments 52, genes associated with integrin-mediated adhesion and cell-surface 
receptor linked signal transduction are varied across our biomaterials (Figure 2b-d). Matrix adhesion via 
integrins mediates survival and drug resistance through activation of survival signaling, such as FAK, Src, 
and ERK 53-55. Disruption of cell adhesion can sensitize tumor cells to drug treatments 10, 32, 56-58. In 3D, we 
generally observed greater drug sensitivity for single cells compared to spheroids (Figure 1e-f), perhaps 
because single cells have lower overall adhesions to surrounding cells and matrix 12. Spheroids and 
tumors can also exhibit multicellular drug resistance through either cell-cell contact-mediated signaling or 
drug diffusion limitations 59, and often co-targeting multiple pathways is required to sensitize the outer, 
matrix-attached cells 31. While our spheroid size was intentionally kept small to minimize diffusion 
limitations, the cell-cell contact inherent to the spheroid structure may provide survival signaling, resulting 
in increased resistance to the RTK-targeted drugs.  
In our hands, gene expression of drug targets was relatively unchanged across our materials. 
Previous work has reported significant changes in gene expression profiles of cell lines cultured in 2D and 
3D laminin-rich ECM 60. This is similar to our own data, where we observed that surface receptor linked 
signal transduction genes vary with both geometry and stiffness, and are universally upregulated during 
culture on TCPS compared to the other biomaterials (Figure 2b). Also, several ligand-receptor pairs were 
co-expressed and enhanced in vivo, including BMP and IL6 signaling (Figure S8a-b). We found that 
growth context determined the expression of cell surface receptors, while expression of the associated 
ligands was dependent on the current assay platform and was more sensitive to stiffness.  
Interestingly, both gene expression and drug sensitivity were regained when cells grown as 
spheroids were dissociated and seeded back onto TCPS (Figure 2a, Figure S8). This demonstrates that 
drug response in the timeframe we examined is dependent on the current environment and not 
necessarily a result of stable genetic alterations or subpopulations resulting from a previous growth 
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condition. In our gene expression data, the xenograft was the most distant from other samples for the 
SkBr3 cells, but not for the MDA-MB-231 cells. This is likely due to the differences in length of time 
required for the xenografts to reach a similar size. The MDA-MB-231 xenograft tumor reached 50 mm3 
within 10 days, and the SkBr3 xenograft took 3 weeks to reach 50 mm3. In an in vivo microenvironment, 
xenograft tumors derived from highly lung metastatic clones of the MDA-MB-231 breast cancer cell line 
have a distinct ECM signature that up-regulates growth factor signaling including TGF-β and VEGF 61. We 
conclude that although gene expression may be useful to inform patient treatment 62, it was not sufficient 
to predict in vitro or pre-clinical drug efficacy here. 
 
Conclusions 
Though the ECM can impart resistance to some RTK inhibitors (sorafenib and lapatinib), MLR 
modeling of phospho-signaling identified combinatorial strategies to combat this resistance (Figure 4e). 
This approach could provide insight into other anti-cancer drugs with varied clinical success, such as 
neratinib 63, 64 and sunitinib 65, 66. However, not all the drugs we tested showed ECM-dependent 
responses, and response to a cytotoxic drug, such as doxorubicin, would have been predicted in a 
simple, quick, cost-effective TCPS assay. It is therefore critical to weigh the monetary cost and time 
burden of the screening approach against the potential benefits. The efficacy of the PD0325901 and 
sorafenib combination therapy would not have been realized using only one screening environment or 
without a systems biology analysis. We envision this approach can be used to identify drugs with poor in 
vivo efficacy early in the drug development pipeline and identify novel drug combinations to overcome 
ECM-induced resistance.  
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Figures 
 
Figure 1. Drug response is dependent upon the biomaterial screening platform. a. Schematic of biomaterial 
drug screening platforms, including TCPS, 2D hydrogels linked with collagen I, and 3D hydrogels with RGD for cell 
adhesion, either with encapsulated single cells or tumor spheroids. Each hydrogel condition was screened at two 
different moduli (2D: 10 or 33 kPa, 3D: 3 or 5 kPa). b. Quantification of mean spheroid diameter for MDA-MB-231 
spheroid growth in polyNIPAAM gels over 14 days. c. Viability of MDA-MB-231 spheroid after 14 days of growth in 
polyNIPAAM, and encapsulation in 3 kPa 3D PEG-MAL hydrogel for 3 days. Green: live cells, red: dead cells. Scale: 
100 μm. d. Experimental time investment required for the different screening platforms. Timeline displays preparation 
time required for each system prior to treating with varying concentrations of drug. e-f. SkBr3 (e) and MDA-MB-231 (f) 
proliferation after 3 days of culture (top row), and GR50 in response to doxorubicin, temsirolimus, sorafenib, and 
lapatinib across the different biomaterial platforms. Red: increase from TCPS control (resistance compared to TCPS), 
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blue: decrease from TCPS control (sensitivity compared to TCPS). TC: TCPS, 10: 10 kPa 2D hydrogel, 33: 33 kPa 
2D hydrogel, 3: 3 kPa 3D hydrogel, 5: 5 kPa 3D hydrogel, +FBS: cells were treated in 10% serum-containing 
medium. Unless noted by +FBS, all cells were treated with drugs in serum-free medium containing EGF and PDGF-
BB. 
 
  
Figure 2. Expression of growth and signal transduction genes distinguishes screening platforms but does 
not explain drug response. a. Clustering and normalized expression values of significantly differentially expressed 
genes across the biomaterial platforms for MDA-MB-231 and SkBr3 cell lines. Genes were ordered by expression on 
TCPS, and each cell line was independently filtered for the top 250 genes by maximum expression across all 
platforms. All significantly differentially expressed genes (p<0.01) are shown in Figure S4. MDA-MB-231 order of 
platforms: spheroids, xenograft, 2D hydrogels at 10 kPa, and 33 kPa, spheroids reseeded to TCPS, TCPS. SkBr3 
order of platforms: xenograft, 2D hydrogels at 10 kPa, and 33 kPa, spheroids, spheroids reseeded to TCPS, TCPS.  
Blue: low expression, red: high expression b. Representative gene set enrichment curves for regulation of growth 
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(MDA-MB-231, TCPS over 3D spheroids) and cell surface receptor linked signal transduction (MDA-MB-231, TCPS 
over 3D spheroids). c-d. Normalized enrichment scores in pairwise platform comparisons for (c) regulation of growth 
(d) and cell surface receptor linked signal transduction. MDA-MB-231 comparisons are enriched in red and SkBr3 
comparisons are in blue. Comparisons are shown as ROW condition over COLUMN (i.e., Top row shows MDA-MB-
231 enrichment on TCPS over other platforms). – indicates  no data. e-h. Expression of known targets for (e) 
lapatinib and (g) sorafenib and previously published off-target genes for (f) lapatinib and (h) sorafenib across the 
biomaterial platforms with linear correlations.  
 
 
Figure 3. Systems analysis reveals that MEK regulates ECM-mediated sorafenib efficacy. a-b. Basal p-ERK 
(pT185/pY187), p-Akt (pS473), and p-JNK (pT183/pY185) signaling for MDA-MB-231 (a) and SkBr3 (b) cell lines 
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across the five screening microenvironments. Black: TCPS, dark blue: 2D gel, green: 3D gel with single cells, teal: 3D 
gel with spheroids, red: 3D gel with spheroids in serum. 2D hydrogel: 33 kPa, 3D hydrogel: 3 kPa. c-d. Phospho-
signaling in response to drug treatment and GR50 for MDA-MB-231 (c) and SkBr3 (d) cell lines. TC: tissue culture 
polystyrene, 2D: 2D PEG-PC hydrogel, 3D: single cells encapsulated in 3D hydrogels, Sp: spheroids encapsulated in 
3D hydrogels, +: spheroids in 3D hydrogels in serum containing medium. Phospho-proteins measured include: CREB 
(pS133), ERK (pT185/pY187), NFκB (pS536), JNK (pT183/pY185), p38 (pT180/pY182), STAT3 (pS727), STAT5A/B 
(pY694/699), Akt (pS473), EGFR (pan Tyr), and MEK1 (pS222). Red: increase compared to vehicle control, blue: 
decrease from vehicle control. e,g. Sorafenib GR50 alone or in combination with SP600125 (JNK inhibitor, 20 μM) or 
PD0325901 (MEK inhibitor, 3 μM) for MDA-MB-231 (e) and (g) SkBr3 cell lines. Black: control, blue: SP600125, red: 
PD0325901. f,h. MLR models of signaling data for MDA-MB-231 (f) and SkBr3 (h). 
 
 
Figure 4. PD0325901 and sorafenib are an effective combination therapy to reduce in vivo tumor burden. a. 
Schematic for tumor induction of the MDA-MB-231 cells, grown first for 7 days, followed by daily drug dosing for 14 
days until a 21-day endpoint. b. Final tumor weight for each drug dosing condition (C: control, S: 10 mg/kg sorafenib, 
PD: 10 mg/kg PD0325901, and co-dosing at either 5 mg/kg or 10 mg/kg of each therapeutic, p = 0.05; two-tailed t-
test on log transformed data). c. Representative images for Ki67 staining in tumors and d. quantification of Ki67 
positive cells in drug treatment groups (S/PD is the 10 mg/kg combination therapy). Scale bar is 50 μm. e. Screening 
for ECM-mediated resistance in drugs like sorafenib can be used in combination with multiple linear regression 
modeling to find combination therapies with the MEK inhibitor PD0325901. Error bars represent mean and SEM, N≥4.  
 
